πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11021481

Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 anta

Nimbus Saturn, Inc. Β· Granted Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11007201

Corticotropin releasing factor receptor antagonists

SPRUCE BIOSCIENCES, INC. Β· Granted Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10981894

Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

CRINETICS PHARMACEUTICALS, INC. Β· Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10973879

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10947206

cGAS antagonist compounds

The Board of Regents of the University of Texas System Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10946009

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Theravance Biopharma R&D IP, LLC Β· Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941159

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10905769

Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10899826

Pharmaceutical compositions for an anti-CGRP antagonist antibody

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10888601

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10881660

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagoni

Corcept Therapeutics Incorporated Β· Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10864217

Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue Dec 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10857231

Formulations of VEG antagonist fusion proteins and method of manufacturing them

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10857205

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10849908

Corticotropin releasing factor receptor antagonists

SPRUCE BIOSCIENCES, INC. Β· Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10836744

Diamide compounds having muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist

Theravance Respiratory Company, LLC Β· Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10828345

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10780095

Compositions and methods for treating disorders of circadian and diurnal rhythms using pro

The Regents of the University of California Β· Granted Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10774128

IL-33 antagonists and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10766877

Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

CRINETICS PHARMACEUTICALS, INC. Β· Granted Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10745397

1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4

Takeda Pharmaceutical Company Limited Β· Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10745394

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10716770

Nicotinic receptor non-competitive antagonists

Catalyst Biosciences, Inc. Β· Granted Tue Jul 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10689373

1,2-substituted cyclopentanes as orexin receptor antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted